Symbols / CYDY
CYDY Chart
About
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 273.13M |
| Enterprise Value | 310.67M | Income | -40.34M | Sales | — |
| Book/sh | -0.10 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -1.19 | PEG | — |
| P/S | — | P/B | -2.26 | P/C | — |
| EV/EBITDA | -16.27 | EV/Sales | — | Quick Ratio | 0.06 |
| Current Ratio | 0.10 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.03 | EPS next Y | -0.18 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-04-14 | ROA | -70.67% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.27B |
| Shs Float | 1.27B | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | 0.45 | 52W Low | 0.19 |
| Beta | 1.27 | Avg Volume | 1.77M | Volume | 19.70K |
| Target Price | — | Recom | None | Prev Close | $0.23 |
| Price | $0.21 | Change | -5.29% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.22
Latest analyst target
3. DCF / Fair value
$0.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.22
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2020-07-06 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2020-04-28 | reit | HC Wainwright & Co. | — → Buy | $4 |
| 2020-04-03 | reit | HC Wainwright & Co. | — → Buy | $3 |
| 2019-12-19 | reit | HC Wainwright & Co. | — → Buy | $2 |
| 2019-09-16 | reit | HC Wainwright & Co. | — → Buy | $1 |
- $17.5M bet on cancer drug leronlimab for tough breast, colon tumors - Stock Titan hu, 05 Mar 2026 13
- CytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below Fifty Day Moving Average - Time to Sell? - MarketBeat Wed, 04 Mar 2026 10
- CytoDyn Boosts Liquidity Through Significant Unregistered Equity Sales - TipRanks hu, 05 Mar 2026 19
- Ex-CytoDyn CEO sentenced to prison, must pay $5.3M restitution as former CRO leader wins new trial - Fierce Biotech Mon, 26 Jan 2026 08
- Ex-CytoDyn CEO Sentenced to 30-Month Prison Term on Fraud, Insider Trading - Genetic Engineering and Biotechnology News ue, 27 Jan 2026 08
- CytoDyn (CYDY) sets 2026 CRC, mTNBC Phase 2 plans after leronlimab survival data - Stock Titan ue, 16 Dec 2025 08
- CytoDyn Secures $30 Million Commitment from Yorkville Advisors - Yahoo Finance Mon, 03 Nov 2025 08
- CytoDyn Inc. SEC 10-Q Report - TradingView Fri, 09 Jan 2026 08
- CytoDyn (OTCMKTS:CYDY) Stock Crosses Above 200-Day Moving Average - Should You Sell? - MarketBeat Fri, 20 Feb 2026 08
- CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle - Fierce Biotech Fri, 27 Jun 2025 07
- CytoDyn (OTCQB: CYDY) inks class action resolution deal, pending court approval - Stock Titan Mon, 01 Dec 2025 08
- Some Research Into Short-Seller Culper Research - Law Street Media hu, 17 Jul 2025 07
- CytoDyn Reaches Settlement in Securities Lawsuit - TipRanks Mon, 01 Dec 2025 08
- Former CytoDyn Official Found Guilty of Securities Fraud - BioSpace hu, 12 Dec 2024 08
- Investor Relations - CytoDyn Inc. Fri, 20 Oct 2017 16
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 9.04M | -30.47M | -64.15M | -191.12M |
| TotalUnusualItems | -445.00K | -13.61M | -8.75M | -3.85M |
| TotalUnusualItemsExcludingGoodwill | -445.00K | -13.61M | -8.75M | -3.85M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 3.75M | -49.84M | -79.82M | -210.82M |
| ReconciledDepreciation | 18.00K | 29.00K | 175.00K | 781.00K |
| ReconciledCostOfRevenue | 0.00 | 20.63M | 53.00K | 0.00 |
| EBITDA | 8.59M | -44.08M | -72.90M | -194.97M |
| EBIT | 8.58M | -44.11M | -73.07M | -195.75M |
| NetInterestIncome | -5.47M | -18.17M | -30.50M | -61.56M |
| InterestExpense | 4.83M | 5.74M | 6.75M | 15.07M |
| InterestIncome | 565.00K | 217.00K | 2.00K | |
| NormalizedIncome | 4.19M | -36.23M | -71.07M | -206.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 3.75M | -49.84M | -79.82M | -210.82M |
| TotalExpenses | -9.66M | 18.06M | 40.58M | 145.67M |
| TotalOperatingIncomeAsReported | -9.66M | -18.06M | -40.58M | -145.40M |
| DilutedAverageShares | 1.24B | 969.51M | 836.53M | 676.90M |
| BasicAverageShares | 1.21B | 969.51M | 836.53M | 676.90M |
| DilutedEPS | 0.00 | -0.05 | -0.10 | -0.31 |
| BasicEPS | 0.00 | -0.05 | -0.10 | -0.31 |
| DilutedNIAvailtoComStockholders | 2.26M | -51.32M | -86.74M | -212.45M |
| NetIncomeCommonStockholders | 2.26M | -51.32M | -86.74M | -212.45M |
| OtherunderPreferredStockDividend | 0.00 | 5.42M | 0.00 | |
| PreferredStockDividends | 1.48M | 1.48M | 1.50M | 1.63M |
| NetIncome | 3.75M | -49.84M | -79.82M | -210.82M |
| NetIncomeIncludingNoncontrollingInterests | 3.75M | -49.84M | -79.82M | -210.82M |
| NetIncomeContinuousOperations | 3.75M | -49.84M | -79.82M | -210.82M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | 3.75M | -49.84M | -79.82M | -210.82M |
| OtherIncomeExpense | -445.00K | -13.61M | -8.75M | -3.85M |
| SpecialIncomeCharges | 407.00K | -13.37M | 0.00 | -3.85M |
| OtherSpecialCharges | 13.37M | 3.85M | 10.63M | |
| WriteOff | 73.49M | 5.03M | ||
| ImpairmentOfCapitalAssets | 0.00 | 10.05M | ||
| RestructuringAndMergernAcquisition | -407.00K | 0.00 | ||
| GainOnSaleOfSecurity | -852.00K | -236.00K | -8.75M | |
| NetNonOperatingInterestIncomeExpense | -5.47M | -18.17M | -30.50M | -61.56M |
| TotalOtherFinanceCost | 1.21M | 12.65M | 23.75M | 46.50M |
| InterestExpenseNonOperating | 4.83M | 5.74M | 6.75M | 15.07M |
| InterestIncomeNonOperating | 565.00K | 217.00K | 2.00K | |
| OperatingIncome | 9.66M | -18.06M | -40.58M | -145.40M |
| OperatingExpense | -9.66M | 18.06M | 19.94M | 145.62M |
| OtherOperatingExpenses | 20.63M | 73.49M | ||
| DepreciationAmortizationDepletionIncomeStatement | 29.00K | 175.00K | 781.00K | 1.80M |
| DepreciationAndAmortizationInIncomeStatement | 29.00K | 175.00K | 781.00K | 1.80M |
| Amortization | 0.00 | 132.00K | ||
| AmortizationOfIntangiblesIncomeStatement | 0.00 | 132.00K | ||
| DepreciationIncomeStatement | 29.00K | 43.00K | ||
| ResearchAndDevelopment | -16.92M | 7.24M | 2.63M | 27.04M |
| SellingGeneralAndAdministration | 7.26M | 10.82M | 17.14M | 44.30M |
| GeneralAndAdministrativeExpense | 7.26M | 10.82M | 17.14M | 44.30M |
| OtherGandA | 3.64M | 4.05M | 6.40M | 27.19M |
| InsuranceAndClaims | 1.24M | 1.85M | 2.40M | 4.51M |
| SalariesAndWages | 2.38M | 4.92M | 8.34M | 12.60M |
| GrossProfit | 0.00 | -20.63M | 213.00K | 0.00 |
| CostOfRevenue | 0.00 | 20.63M | 53.00K | 0.00 |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 266.00K |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 266.00K |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 286.00K | 443.00K | 443.00K | 443.00K |
| OrdinarySharesNumber | 1.25B | 1.06B | 918.61M | 719.59M |
| ShareIssued | 1.25B | 1.06B | 919.05M | 720.03M |
| NetDebt | 15.30M | 26.68M | 32.59M | 32.01M |
| TotalDebt | 27.34M | 30.08M | 35.55M | 36.80M |
| TangibleBookValue | -96.04M | -116.76M | -109.50M | -94.53M |
| InvestedCapital | -68.84M | -86.97M | -74.37M | -58.16M |
| WorkingCapital | -52.64M | -73.37M | -108.99M | -112.65M |
| NetTangibleAssets | -96.04M | -116.76M | -109.50M | -94.53M |
| CapitalLeaseObligations | 141.00K | 283.00K | 422.00K | 556.00K |
| CommonStockEquity | -96.04M | -116.76M | -109.50M | -94.40M |
| TotalCapitalization | -96.04M | -116.76M | -108.79M | -94.40M |
| TotalEquityGrossMinorityInterest | -96.04M | -116.76M | -109.50M | -94.40M |
| StockholdersEquity | -96.04M | -116.76M | -109.50M | -94.40M |
| TreasuryStock | 0.00 | 0.00 | 0.00 | 0.00 |
| RetainedEarnings | -887.79M | -891.53M | -841.69M | -766.13M |
| AdditionalPaidInCapital | 790.50M | 773.71M | 731.27M | 671.01M |
| CapitalStock | 1.25M | 1.06M | 919.00K | 720.00K |
| CommonStock | 1.25M | 1.06M | 919.00K | 720.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 114.09M | 127.89M | 120.79M | 123.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 43.57M | 43.71M | 997.00K | 422.00K |
| OtherNonCurrentLiabilities | 43.57M | 43.57M | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 141.00K | 997.00K | 422.00K |
| LongTermCapitalLeaseObligation | 0.00 | 141.00K | 283.00K | 422.00K |
| LongTermDebt | 714.00K | |||
| CurrentLiabilities | 70.52M | 84.18M | 119.80M | 123.16M |
| OtherCurrentLiabilities | 145.00K | 25.00K | 79.00K | 64.00K |
| CurrentDebtAndCapitalLeaseObligation | 27.34M | 29.93M | 34.56M | 36.38M |
| CurrentCapitalLeaseObligation | 141.00K | 142.00K | 139.00K | 134.00K |
| CurrentDebt | 27.20M | 29.79M | 34.42M | 36.24M |
| OtherCurrentBorrowings | 27.20M | 29.79M | 34.42M | 36.24M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 278.00K | 208.00K | 335.00K | 1.52M |
| PayablesAndAccruedExpenses | 42.75M | 54.01M | 84.83M | 85.20M |
| CurrentAccruedExpenses | 19.79M | 17.66M | 16.79M | 13.25M |
| InterestPayable | 18.15M | 15.23M | 10.60M | 5.97M |
| Payables | 22.96M | 36.35M | 68.03M | 71.95M |
| OtherPayable | 139.00K | 134.00K | ||
| DividendsPayable | 8.27M | 6.79M | 5.31M | 3.98M |
| AccountsPayable | 14.69M | 29.56M | 62.73M | 67.97M |
| TotalAssets | 18.05M | 11.14M | 11.29M | 29.18M |
| TotalNonCurrentAssets | 169.00K | 321.00K | 487.00K | 18.80M |
| OtherNonCurrentAssets | 169.00K | 321.00K | 487.00K | 18.67M |
| GoodwillAndOtherIntangibleAssets | 0.00 | 132.00K | 1.65M | |
| OtherIntangibleAssets | 132.00K | 1.65M | ||
| NetPPE | 609.00K | 846.00K | ||
| GrossPPE | 609.00K | 846.00K | ||
| OtherProperties | 609.00K | 846.00K | ||
| CurrentAssets | 17.88M | 10.81M | 10.80M | 10.52M |
| RestrictedCash | 0.00 | 6.70M | 6.51M | 0.00 |
| PrepaidAssets | 3.98M | 1.00M | 1.76M | 6.28M |
| Inventory | 17.93M | 93.48M | ||
| WorkInProcess | 1.67M | 65.39M | ||
| RawMaterials | 16.26M | 28.09M | ||
| Receivables | 2.00M | 0.00 | ||
| OtherReceivables | 2.00M | |||
| CashCashEquivalentsAndShortTermInvestments | 11.90M | 3.11M | 2.54M | 4.23M |
| CashAndCashEquivalents | 11.90M | 3.11M | 2.54M | 4.23M |
| CashFinancial | 11.90M | 3.11M | 2.54M | 4.23M |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.77M | -10.98M | -25.11M | -77.72M |
| RepaymentOfDebt | -710.00K | 0.00 | 0.00 | -950.00K |
| IssuanceOfDebt | 0.00 | 2.01M | 895.00K | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 9.14M | 25.79M | 41.20M |
| CapitalExpenditure | -122.00K | |||
| InterestPaidSupplementalData | 25.00K | 45.00K | 19.00K | 63.00K |
| EndCashPosition | 11.90M | 9.81M | 9.05M | 4.23M |
| BeginningCashPosition | 9.81M | 9.05M | 4.23M | 33.94M |
| ChangesInCash | 2.09M | 766.00K | 4.82M | -29.71M |
| FinancingCashFlow | 10.85M | 11.75M | 29.93M | 48.01M |
| CashFlowFromContinuingFinancingActivities | 10.85M | 11.75M | 29.93M | 48.01M |
| NetOtherFinancingCharges | 300.00K | -788.00K | ||
| ProceedsFromStockOptionExercised | 11.56M | 300.00K | 3.25M | 6.82M |
| CashDividendsPaid | 0.00 | -243.00K | ||
| PreferredStockDividendPaid | 0.00 | -243.00K | ||
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 9.14M | 25.79M | 41.20M |
| CommonStockIssuance | 0.00 | 9.14M | 25.79M | 41.20M |
| NetIssuancePaymentsOfDebt | -710.00K | 2.01M | 895.00K | 0.00 |
| NetShortTermDebtIssuance | -710.00K | 2.01M | 895.00K | |
| ShortTermDebtPayments | -710.00K | 0.00 | ||
| ShortTermDebtIssuance | 0.00 | 2.01M | 895.00K | |
| NetLongTermDebtIssuance | 0.00 | 99.05M | ||
| LongTermDebtPayments | 0.00 | -950.00K | ||
| LongTermDebtIssuance | 0.00 | 100.00M | ||
| InvestingCashFlow | 0.00 | 0.00 | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | -122.00K | ||
| NetIntangiblesPurchaseAndSale | 0.00 | |||
| PurchaseOfIntangibles | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | -122.00K | ||
| PurchaseOfPPE | 0.00 | -122.00K | ||
| OperatingCashFlow | -8.77M | -10.98M | -25.11M | -77.72M |
| CashFlowFromContinuingOperatingActivities | -8.77M | -10.98M | -25.11M | -77.72M |
| ChangeInWorkingCapital | -16.17M | 11.66M | -1.20M | -4.78M |
| ChangeInPayablesAndAccruedExpense | -11.33M | 10.77M | -3.10M | -2.71M |
| ChangeInPrepaidAssets | -4.84M | 893.00K | 1.90M | -4.12M |
| ChangeInInventory | 0.00 | 2.06M | -79.36M | |
| ChangeInReceivables | 0.00 | 0.00 | ||
| OtherNonCashItems | 4.47M | 37.39M | 19.98M | 17.58M |
| StockBasedCompensation | 1.61M | 2.42M | 4.28M | 6.24M |
| AssetImpairmentCharge | 20.63M | 73.49M | 15.08M | |
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 18.00K | 29.00K | 175.00K | 781.00K |
| DepreciationAndAmortization | 18.00K | 29.00K | 175.00K | 781.00K |
| AmortizationCashFlow | 0.00 | 132.00K | ||
| AmortizationOfIntangibles | 0.00 | 132.00K | ||
| Depreciation | 18.00K | 29.00K | 43.00K | |
| OperatingGainsLosses | 2.03M | 20.29M | 14.07M | 37.38M |
| GainLossOnInvestmentSecurities | 852.00K | 236.00K | 8.76M | |
| NetForeignCurrencyExchangeGainLoss | 1.18M | 6.68M | 5.31M | 37.38M |
| NetIncomeFromContinuingOperations | 3.75M | -49.84M | -79.82M | -210.82M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CYDY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|